Disclosed in the present invention is a method for preparing fosfomycin ammonium salts, comprising the following steps of: in an organic solvent, reacting fosfomycin phenylethylamine with an isocyanate, an isothiocyanate, a ketene, a dimer of an isocyanate, a dimer of an isothiocyanate, or a dimer of a ketene, and tromethamine

The present invention is antibiotic compositions ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside preferably amikacin are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

The present invention is antibiotic compositions ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside preferably amikacin are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

The present invention is antibiotic compositions ventilator based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside preferably amikacin are administered via an in-line nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

The present invention is antibiotic compositions ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside preferably amikacin are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

The present invention is antibiotic compositions ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside preferably amikacin are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

The present invention relates to a solid fosfomycin pharmaceutical composition stable in front the coloration suitable for diabetics and not entailing gastrointestinal problems.The pharmaceutical composition of this invention comprises fosfomycin trometamol glycine and optionally other excipients as sucralose silice dioxide polyvinylpyrrolidone and flavour; and is substantially free from sugars and sugar alcohols as sucrose fructose glucose xylitol mannitol sorbitol or mixtures thereof.